Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou(Tongji University), Shengxiang Ren(Tongji University), Wei Li(Guangdong Pharmaceutical University), Jun Zhang(OSF HealthCare), Wei Shi(Jiangsu Hengrui Medicine (China)), Xin Li(Zhejiang Chinese Medical University), Xinyu Liu(Tongji University), Fei Li(Nanchang University), Xing Sun(Jiangsu Hengrui Medicine (China)), Kan Huang(Fudan University Shanghai Cancer Center), Yaxin Yu(Shanghai Medical College of Fudan University), Xinlei Cai(Westlake University), Yingxue Chen(Shanghai Medical College of Fudan University), Zican Dai(Shanghai Medical College of Fudan University), Jia Yu(Tongji University), Jiayu Li(Tongji University), Chongyang Li(Shanghai Medical College of Fudan University), Zaiyong Wang(Jiangsu Hengrui Medicine (China)), Rongfu Mao(Jiangsu Hengrui Medicine (China)), Tao Jiang(Shanghai Pulmonary Hospital), Zhe Zhang(Jiangsu Hengrui Medicine (China)), Libo Luo(Tongji University), Ning He(Jiangsu Hengrui Medicine (China)), Shiqi Mao(Tongji University), Wanying Wang(Tongji University), Chuchu Shao(Tongji University), Feng He(Jiangsu Hengrui Medicine (China)), Keyi Jia(Tongji University)
Cited by 78
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae
|Cell Metabolism|2019|521
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Targeting the untargetable KRAS in cancer therapy
|Acta Pharmaceutica Sinica B|2019|352